Global Chondrosarcoma Market Research Report Information, by types (Conventional chondrosarcoma, Clear cell chondrosarcoma, Myxoid chondrosarcoma, Mesenchymal chondrosarcoma, Dedifferentiated chondrosarcoma, and others), by diagnosis (Biopsy, Imaging, and others), by treatment (Surgery, Therapies, Hemipelvectomy, and others), by end user (hospitals and clinics, medical research centers, academic institutes, and others) - Forecast till 2030

Global Chondrosarcoma Market Overview

The Global Chondrosarcoma Market is projected to reach USD 1,321.4 Million by 2030 at 6.8% CAGR during the forecast period 2022-2030.

Chondrosarcoma is a rare type of bone cancer that consist predominantly of cartilage. It mostly affect pelvis, upper arms (humerus), thighs (femur), ribs, and shoulder blades (scapula) and is the most common in people older than 40 years.

Rising funding for R&D and clinical trials as well as FDA approvals are major driving forces for global chondrosarcoma market. Major players are funding large amount of money in new product development for effective cure that is another key driver for the market.

In August 2022, the European Commission (EC) gave orphan medicinal product designation to Inhibrx, Inc. for INBRX-109 in chondrosarcoma following a positive opinion from the European Medicines Agency (EMA). The EC grants orphan designation to drugs and biologics intended for the safe and effective treatment, prevention, or diagnosis of a disease that is life-threatening or chronically debilitating, impacting fewer than five in 10,000 patients in the European Union. Orphan drug designation in the EU can provide certain benefits, such as reduced regulatory fees, clinical protocol assistance, and up to ten years of market exclusivity upon regulatory approval. Chondrosarcoma is an orphan bone cancer that accounts for roughly 2,800 new cases each year in the U.S. and EU together. For this condition, there are no approved therapies.

In May 2023, Servier will be showcasing new data across its robust global oncology portfolio at ASCO – June 2-6th designed to bring tomorrow closer to our patients with cancer from all around the globe–. These latest data, including plenary session selection indicating Servier’s expansive oncology pipeline &portfolio as well as the company’s commitment to improving outcomes for underserved high unmet medical needs cancer types in hard-to-treat settings, have been submitted for consideration by ASCO abstract reviewers fare indicative of what we want these conditions in order get a better response from them. A breaking abstract with results from the Phase III INDIGO study of vorasidenib among patients with residual or recurrent grade II IDH-mutant glioma will also be presented at ASCO.

Study objectives of Global Chondrosarcoma Market:

• To provide detailed analysis of the global Chondrosarcoma market structure with historical and forecast revenue for the next 6 years of the various segments and sub-segments of the Chondrosarcoma market


• To provide insights about the key drivers, restraints, opportunities and challenges affecting the growth of the global Chondrosarcoma market


• To provide analysis of the market with respect to four main geographies and their countries - America, Europe, Asia-Pacific, and Middle East & Africa.


• To provide detailed analysis of the market segmented by types, diagnosis, treatment, end user and its sub-segments.


• To provide a detailed analysis of global Chondrosarcoma market mainly based on Value chain analysis, Porter’s five forces, Price analysis, and Supply Chain analysis etc.


• To provide a detailed country level analysis of the market with respect to the current market size and future prospects.


• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Chondrosarcoma market


• To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the Chondrosarcoma market

FIGURE 1    GLOBAL CHONDROSARCOMA MARKET SHARE BY TYPES, 2016 (%)

Intended Audience:

• Chondrosarcoma medicine manufacturers


• Chondrosarcoma medicine and treatment providers


• Hospitals and clinics


• Medical Research laboratories


• Research and Development (R&D) Companies


• Market Research and Consulting Service Providers


• Potential Investors

Research Methodology:

 Sources: National Center for Biotechnology Information, National Kidney Foundation, Inc., CheckOrphan, Directorate of Industries, Annual report, White paper, Company Presentation

Global Chondrosarcoma Market Segmentation

Global chondrosarcoma market has been segmented on the basis of types which comprises of conventional chondrosarcoma, clear cell chondrosarcoma, myxoid chondrosarcoma, mesenchymal chondrosarcoma, de-differentiated chondrosarcoma.

On the basis of diagnosis, it is segmented into biopsy, imaging, and others. Biopsy is further sub-segmented into shave open biopsy, core needle biopsy, and others. Imaging is further sub-segmented into X-Ray, Computed Tomography Scan (CT scan), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET) Scan, and others.

On the basis of treatment, the market has been segmented into intensive surgery, therapies, hemipelvectomy, and others. Therapies are further sub-segmented into physical therapy, radiation therapy, chemotherapy, and others. Hemipelvectomy is further sub-segmented into external hemipelvectomy, internal hemipelvectomy, and others.

On the basis of end user, it is segmented into hospitals and clinics, medical research centers, academic institutes, and others.

Regional Analysis of Global Chondrosarcoma Market     

Considering the global scenario of the market, North America holds the largest market share owing to various factors such as increasing prevalence of chondrosarcoma and increasing investment in R&D. Europe is the second largest market due to advanced healthcare facilities where the countries like Germany and UK are holding the largest market share. New cases of chondrosarcoma are rising in Asia Pacific region. Additionally, improving healthcare infrastructure and rising healthcare expenditure are driving the growth for Asia Pacific chondrosarcoma market. Due to low knowledge of disease and treatment, Middle East and Africa (ME&A) is likely to have a limited growth in the market.

Key Players for Global Chondrosarcoma Market   

Some of the key players in this market are: 

• Abbott. (US)


• AbbVie Inc. (US)


• Akorn, Inc. (US)


• Agios, Inc. (US)


• Baxter (US)


• Bayer AG (US)


• Epizyme, Inc. (US)


• Novartis AG (Switzerland)


• Mylan N.V. (US)

The report for Global Chondrosarcoma Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain deeper insight to the market and industry performance. The report gives a clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions